Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8431 to 8445 of 9042 results

  1. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

    Technology appraisal guidance
    Discontinued

  2. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  3. Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

    Discontinued Reference number: GID-TA10164

    Technology appraisal guidance
    Discontinued

  4. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued Reference number: GID-TA10166

    Technology appraisal guidance
    Discontinued

  5. Rucaparib for treating ovarian, fallopian tube or peritoneal cancer that has a BRCA mutation [ID1184]

    Discontinued Reference number: GID-TA10168

    Technology appraisal guidance
    Discontinued

  6. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued Reference number: GID-TA10179

    Technology appraisal guidance
    Discontinued

  7. NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]

    Discontinued Reference number: GID-TA10183

    Technology appraisal guidance
    Discontinued

  8. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued

  9. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued Reference number: GID-TA10110

    Technology appraisal guidance
    Discontinued

  11. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued Reference number: GID-TA10737

    Technology appraisal guidance
    Discontinued

  12. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    Discontinued Reference number: GID-TA10843

    Technology appraisal guidance
    Discontinued

  14. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  15. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued